The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anlotinib in combination with epirubicin followed by maintenance anlotinib versus placebo plus epirubicin as first-line treatment for advanced soft tissue sarcoma (STS): A randomized, double-blind, parallel-controlled, phase III study.
 
Yuhong Zhou
No Relationships to Disclose
 
Xiaohui Niu
No Relationships to Disclose
 
Yu Jiang
No Relationships to Disclose
 
Bin LI
No Relationships to Disclose
 
Wei Luo
No Relationships to Disclose
 
Jilong Yang
No Relationships to Disclose
 
Xiaowei Zhang
No Relationships to Disclose
 
Xianan Li
No Relationships to Disclose
 
Zhengfu Fan
No Relationships to Disclose
 
Yongchun Song
No Relationships to Disclose
 
Renbing Jiang
No Relationships to Disclose
 
Rutian Li
No Relationships to Disclose
 
Meiyu Fang
No Relationships to Disclose
 
Guofan Qu
No Relationships to Disclose
 
Dongyuan Zhu
No Relationships to Disclose
 
Di Wu
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Zhen Huang
No Relationships to Disclose
 
Jiating Hu
Employment - Chia Tai Tianqing Pharmaceutical Group Co.Ltd.
 
Xiaojing Wan
Employment - Chia Tai Tianqing Pharmaceutical Group Co.Ltd.